Doseology Announces Revocation of MCTO and Adoption of Semi-Annual Financial Reporting
Doseology aims to reduce reporting costs and administrative work while retaining annual and six-month financial reports.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Doseology Sciences (OTCQB: DOSEF) announced the revocation of its management cease trade order and plans to adopt semi-annual financial reporting. The British Columbia Securities Commission revoked the order issued October 29, 2026, after Doseology filed its required annual disclosures on November 3, 2026, for the fiscal year ended June 30, 2026. The company is no longer listed as in default in its Canadian reporting jurisdictions that maintain such lists.
Under the Semi-Annual Reporting Pilot Program, Doseology will skip interim statements and related management discussion for the periods ending September 30, 2026, and March 31, 2027, and subsequent three- and nine-month periods. Audited annual statements and six-month interim reports will continue. Doseology confirms it meets the eligibility criteria and aims to reduce reporting costs and administrative work. Material-change disclosure obligations remain in place.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointThe BCSC revoked the management cease trade order following completion of required annual filings.
- Minor pointDoseology is no longer listed as in default in Canadian reporting jurisdictions maintaining such lists.
- Minor point. Forward-looking: it has not happened yet and may not happen.Semi-annual reporting adoption aims to reduce administrative and financial burdens, the company says.
Negative
- Moderate point. Forward-looking: it has not happened yet and may not happen.Three- and nine-month interim financial statements and related management discussion will no longer be filed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Kelowna, British Columbia--(Newsfile Corp. - November 5, 2026) - Doseology Sciences Inc. (CSE: MOOD) (OTCQB: DOSEF) (FSE: VU70) ("Doseology" or the "Company") announces revocation of the management cease trade order ("MCTO") previously issued on October 29, 2026; and its intention to voluntarily adopt the Semi-Annual Reporting ("SAR") Pilot Program pursuant to Coordinated Blanket Order 51-933 Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers (the "Blanket Order").
MCTO Revocation:
The British Columbia Securities Commission ("BCSC") has revoked the MCTO previously issued on October 29, 2026 under National Policy 12-203 - Management Cease Trade Orders.
The issuance of the revocation order follows the filing by the Company of its audited annual financial statements for its fiscal year ended June 30, 2026 with related management's discussion and analysis and associated Chief Executive Officer and Chief Financial Officer certifications on November 3, 2026 (the "Required Filings"). Copies of the Required Filings are available under the Company's SEDAR+ profile at www.sedarplus.ca.
The Company is also no longer listed as being in default on the BCSC's reporting issuer list and on the reporting issuer list, or default list, of each jurisdiction of Canada in which it is a reporting issuer to the extent that such jurisdiction maintains a list.
Semi-Annual Reporting Adoption:
The SAR Pilot Program allows eligible venture issuers listed on the TSX Venture Exchange or the Canadian Securities Exchange to voluntarily transition from quarterly to semi-annual financial reporting. As a result, the Company will no longer be required to prepare and file interim financial statements and related management's discussion and analysis ("MD&A") for its three-month and nine-month periods. By adopting the SAR Pilot Program, the Company aims to reduce the administrative and financial burden associated with quarterly reporting while maintaining its commitment to providing timely and transparent disclosure to shareholders.
The Company's financial year end is June 30. The Company will not file interim financial statements and related MD&A for the three-month period ending September 30, 2026 and its nine-month period ending March 31, 2027, and the three-month and nine-month periods going forward. Should the Company cease to continue participating in the SAR Pilot Program, it will announce it in a future news release. The Company will continue to file audited annual financial statements and six-month interim financial reports.
The Company confirms it meets the SAR Pilot Program's eligibility criteria, which include being a venture issuer with annual revenues of less than
This news release is being filed pursuant to the Blanket Order.
About Doseology Sciences Inc.(CSE: MOOD) (OTCQB: DOSEF) (FSE: VU70)
Doseology Sciences Inc. specializes in pouch-based oral stimulant and cognitive support products. The rapidly expanding oral stimulant pouch sector is gaining momentum as consumers seek modern, discreet alternatives to traditional delivery formats. Unlike combustible tobacco or vape products, oral stimulant pouches are smokeless and vapor-free, providing an alternative delivery method without inhalation.
From a market perspective, the oral pouch category is experiencing strong global growth as consumers increasingly prioritize convenience, portability, and format innovation. The pouch sector represents one of the most dynamic and high-growth areas in modern functional consumer products.
For more information visit:
Corporate: www.doseology.com
On behalf of the Board of Directors,
Kareem Baalbaki
Interim CEO
Doseology Sciences Inc.
Investor & Media Contact:
Email: hello@doseology.com
Phone: 825.800.0115
No securities regulatory authority has either approved or disapproved of the contents of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/322708
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Why was Doseology's management cease trade order revoked?
The BCSC revoked the order after Doseology completed its required annual filings on November 3, 2026. These included audited financial statements for the fiscal year ended June 30, 2026, related management discussion and analysis, and CEO and CFO certifications.
What financial reports will Doseology file under semi-annual reporting?
Doseology will continue filing audited annual financial statements and six-month interim financial reports. It will not file interim statements and related management discussion for the three-month period ending September 30, 2026, the nine-month period ending March 31, 2027, or subsequent three- and nine-month periods.
What makes Doseology eligible for the Semi-Annual Reporting Pilot Program?
Doseology confirms it meets the program's criteria, including venture-issuer status, annual revenues of less than $10 million, a disclosure record exceeding 12 months, and completion of all required periodic and timely continuous disclosure documents.
How will Doseology notify investors if it leaves the semi-annual reporting program?
Doseology will announce its departure from the Semi-Annual Reporting Pilot Program in a future news release if it stops participating.